Successful switches are as much an art as a science; for switch teams to execute effectively, they must be constantly evolving best practices. DGE’s Rx-to-OTC Switch Symposium is the premier event for learning about all aspects of a switch, from recent approvals and trends, to navigating the NDA process, to packaging the final product. This unique conference will ensure that your team gives proper attention to a sometimes-overlooked brand strategy. Don’t miss out on the ONLY learning and networking event focusing entirely on this topic!
- Gain knowledge about the complex process for an Rx to OTC switch and the changing landscape
- Identify best practices to implement a well-executed strategy for a successful Rx to OTC switch
- Establish the best marketing and branding strategies to commercialize your brand while staying in compliance with regulatory
- Learn from top experts who have had success with a switch
- Share case studies and success stories and how to implement these strategies
- Bring back innovative marketing ideas to share valuable information with your team
This livestream conference is designed for life science professionals with the following responsibilities:
- Rx-to-OTC Switch/Rx Access
- Regulatory Affairs
- Brand Management
- Product Management
- Brand Marketing
- Legal Affairs
- Consumer Healthcare Products
- Medical/Scientific Affairs
- Consumer Marketing
- Clinical Development
- Clinical Trial
- Drug Safety
- Research and Development
- Project Management
- Portfolio Strategy
- Product Development
- Drug Delivery Technology
- Packaging & Labeling
- Business Strategy




















Rx-to-OTC Switch can be a high-risk/high-reward proposition. In order to maximize the potential of an Rx to OTC switch, it is critical to ensure that the proposed switch is addressing an unmet consumer need. In addition to this, a switch must make strong financial sense for your company.
Rx companies with switchable prescription assets can achieve long-term life cycle value by pursuing an Rx to OTC switch. Driving success with OTC drugs requires different capabilities than driving success with Rx drugs, however, and therefore a strategic assessment of whether to build, borrow, or buy those capabilities is a critical part of the Rx to OTC switch process.
• Discuss how Rx and OTC capabilities differ
• Analyze the options that should be considered to ensure that OTC capabilities are established for the switch
• Consider partner selection if you choose to partner with an OTC company
This window is secured by 256 bit encryption on a PCI compliant network. Click here to view this window in its own page.